NCT04351347 The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
| NCT ID | NCT04351347 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Tanta University |
| Condition | COVID |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2020-06-16 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 300 participants in total. It began in 2020-06-16 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Efficacy of Ivermectin in larger doses in COVID-19 treatment
Eligibility Criteria
Inclusion Criteria: * Patients with covid 19 Exclusion Criteria: * Allergy or side effects to treatment
Contact & Investigator
sherief Abd-Elsalam, Ass. Prof.
PRINCIPAL INVESTIGATOR
Tanta University - Faculty of Medicine
Frequently Asked Questions
Who can join the NCT04351347 clinical trial?
This trial is open to participants of all sexes, studying COVID. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04351347 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT04351347 currently recruiting?
Yes, NCT04351347 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT04351347 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT04351347 clinical trial?
NCT04351347 is sponsored by Tanta University. The principal investigator is sherief Abd-Elsalam, Ass. Prof. at Tanta University - Faculty of Medicine. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.